<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>Patient Summary Dashboard - PATIENT, DONALD</title>
<style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 10px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.2);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #4a5568 0%, #2d3748 100%);
            color: white;
            padding: 30px;
            text-align: center;
        }
        
        .header h1 {
            font-size: 32px;
            margin-bottom: 10px;
        }
        
        .header p {
            font-size: 14px;
            opacity: 0.9;
        }
        
        .patient-info {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            padding: 30px;
            background: #f7fafc;
            border-bottom: 3px solid #e2e8f0;
        }
        
        .info-card {
            background: white;
            padding: 20px;
            border-radius: 8px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
            border-left: 4px solid #4299e1;
        }
        
        .info-card h3 {
            color: #2d3748;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 10px;
        }
        
        .info-card p {
            font-size: 18px;
            font-weight: 600;
            color: #4a5568;
        }
        
        .content {
            padding: 30px;
        }
        
        .section {
            margin-bottom: 40px;
        }
        
        .section h2 {
            color: #2d3748;
            font-size: 24px;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 2px solid #e2e8f0;
        }
        
        .diagnosis-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 15px;
        }
        
        .diagnosis-item {
            background: #fff5f5;
            border-left: 4px solid #f56565;
            padding: 15px;
            border-radius: 5px;
        }
        
        .diagnosis-item.resolved {
            background: #f0fff4;
            border-left-color: #48bb78;
        }
        
        .diagnosis-item h4 {
            color: #2d3748;
            margin-bottom: 8px;
        }
        
        .diagnosis-item p {
            font-size: 14px;
            color: #718096;
        }
        
        .timeline {
            position: relative;
            padding-left: 40px;
        }
        
        .timeline::before {
            content: '';
            position: absolute;
            left: 10px;
            top: 0;
            bottom: 0;
            width: 2px;
            background: #cbd5e0;
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 30px;
            padding-left: 20px;
        }
        
        .timeline-item::before {
            content: '';
            position: absolute;
            left: -34px;
            top: 5px;
            width: 12px;
            height: 12px;
            border-radius: 50%;
            background: #4299e1;
            border: 3px solid white;
            box-shadow: 0 0 0 2px #4299e1;
        }
        
        .timeline-item.critical::before {
            background: #f56565;
            box-shadow: 0 0 0 2px #f56565;
        }
        
        .timeline-date {
            font-weight: 600;
            color: #4299e1;
            margin-bottom: 5px;
        }
        
        .timeline-content {
            background: #f7fafc;
            padding: 15px;
            border-radius: 5px;
            border: 1px solid #e2e8f0;
        }
        
        .lab-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 15px;
        }
        
        .lab-table th {
            background: #4a5568;
            color: white;
            padding: 12px;
            text-align: left;
            font-weight: 600;
        }
        
        .lab-table td {
            padding: 10px 12px;
            border-bottom: 1px solid #e2e8f0;
        }
        
        .lab-table tr:hover {
            background: #f7fafc;
        }
        
        .status-badge {
            display: inline-block;
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .status-active {
            background: #c6f6d5;
            color: #22543d;
        }
        
        .status-completed {
            background: #bee3f8;
            color: #2c5282;
        }
        
        .status-critical {
            background: #fed7d7;
            color: #742a2a;
        }
        
        .alert {
            background: #fef5e7;
            border-left: 4px solid #f39c12;
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
        }
        
        .alert h4 {
            color: #d68910;
            margin-bottom: 8px;
        }
        
        .footer {
            background: #2d3748;
            color: white;
            text-align: center;
            padding: 20px;
            font-size: 12px;
        }
        
        @media print {
            body {
                background: white;
                padding: 0;
            }
            .container {
                box-shadow: none;
            }
        }
    </style>
</head>
<body>
<div class="container">
<div class="header">
<h1>PATIENT MEDICAL SUMMARY</h1>
<p>Regional New Natalieborough Hospital | Electronic Health Record</p>
<p>Generated: October 22, 2016 | Report ID: EHR-2016-10-789012</p>
</div>
<div class="patient-info">
<div class="info-card">
<h3>Patient Name</h3>
<p>PATIENT, DONALD</p>
</div>
<div class="info-card">
<h3>Medical Record Number</h3>
<p>123456789</p>
</div>
<div class="info-card">
<h3>Date of Birth</h3>
<p>XX/XX/1955 (61 years)</p>
</div>
<div class="info-card">
<h3>Sex</h3>
<p>Male</p>
</div>
<div class="info-card">
<h3>Primary Physician</h3>
<p>Dr. David Nicholas, MD</p>
</div>
<div class="info-card">
<h3>Last Visit</h3>
<p>10/22/2016</p>
</div>
</div>
<div class="content">
<!-- Active Diagnoses -->
<div class="section">
<h2>üî¥ Active &amp; Resolved Diagnoses</h2>
<div class="diagnosis-list">
<div class="diagnosis-item">
<nav><a href="#prostatic-adenocarcinoma">Prostatic Adenocarcinoma (Active)</a></nav>
<p><strong>Stage:</strong> cT2a N0 M0</p>
<p><strong>Grade:</strong> Gleason 3+4=7 (Grade Group 2)</p>
<p><strong>Diagnosed:</strong> July 2015</p>
<p><strong>Status:</strong> Post-treatment surveillance, PSA 0.32 ng/mL</p>
</div>
<div class="diagnosis-item resolved">
<nav><a href="#rectal-adenocarcinoma">Rectal Adenocarcinoma (Resolved)</a></nav>
<p><strong>Stage:</strong> pT2 N1a M0 (Stage IIIA)</p>
<p><strong>Treatment:</strong> Neoadjuvant chemoRT + APR (1987)</p>
<p><strong>Status:</strong> NED x29 years, colostomy present</p>
</div>
<div class="diagnosis-item resolved">
<nav><a href="#appendiceal-adenocarcinoma">Appendiceal Adenocarcinoma (Resolved)</a></nav>
<p><strong>Histology:</strong> Mucinous adenocarcinoma</p>
<p><strong>Treatment:</strong> Appendectomy + Xeloda (2005-2006)</p>
<p><strong>Status:</strong> NED x10 years</p>
</div>
<div class="diagnosis-item">
<nav><a href="#lynch-syndrome">Lynch Syndrome (HNPCC)</a></nav>
<p><strong>Mutation:</strong> MSH2 c.942+3A&gt;T (Pathogenic)</p>
<p><strong>Inheritance:</strong> Autosomal dominant</p>
<p><strong>Status:</strong> Active surveillance protocol</p>
</div>
</div>
</div>
<!-- Alert Box -->
<div class="alert">
<h4>‚ö†Ô∏è Lynch Syndrome Surveillance Required</h4>
<p>Patient requires enhanced cancer surveillance due to hereditary MSH2 mutation. 
                   Annual colonoscopy, urinalysis with cytology, and dermatologic exams recommended. 
                   First-degree relatives should be offered genetic counseling and testing.</p>
</div>
<!-- Treatment Timeline -->
<div class="section">
<h2>üìÖ Treatment Timeline</h2>
<div class="timeline">
<div class="timeline-item critical" id="appendiceal-adenocarcinoma">
<div class="timeline-date">August 15, 1987</div>
<div class="timeline-content">
<h4>Abdominoperineal Resection (APR)</h4>
<p>Left-sided rectal adenocarcinoma. Neoadjuvant 5FU/mitomycin + 3000 cGy radiation.</p>
<p><strong>Pathology:</strong> pT2N1a (2/18 nodes positive), Stage IIIA</p>
<p><strong>Surgeon:</strong> Dr. William Thompson, MD</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">June 15, 2005</div>
<div class="timeline-content">
<h4>Laparoscopic Appendectomy</h4>
<p>Appendiceal adenocarcinoma with mucinous features discovered.</p>
<p>Patient declined right hemicolectomy, opted for close surveillance.</p>
</div>
</div>
<div class="timeline-item" id="lynch-syndrome">
<div class="timeline-date">January 2006</div>
<div class="timeline-content">
<h4>Adjuvant Chemotherapy - Capecitabine</h4>
<p>6 cycles completed. Tolerated well with Grade 1-2 hand-foot syndrome.</p>
<p><strong>Outcome:</strong> No evidence of disease (NED)</p>
</div>
</div>
<div class="timeline-item critical">
<div class="timeline-date">July 26, 2015</div>
<div class="timeline-content">
<h4>Transperineal Prostate Biopsy</h4>
<p>6 cores obtained. Positive for adenocarcinoma in 1/6 cores (right mid gland).</p>
<p><strong>Pathology:</strong> Gleason 3+4=7 (Grade Group 2), 45% core involvement</p>
<p><strong>PSA at diagnosis:</strong> 14.76 ng/mL</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">September 20, 2015</div>
<div class="timeline-content">
<h4>Androgen Deprivation Therapy (ADT) Initiated</h4>
<p>Leuprolide acetate (Lupron Depot) 22.5 mg IM every 3 months x 6 months</p>
<p><strong>Goal:</strong> Testosterone suppression prior to radiation therapy</p>
</div>
</div>
<div class="timeline-item critical">
<div class="timeline-date">November 2, 2015 - January 15, 2016</div>
<div class="timeline-content">
<h4>External Beam Radiation Therapy (VMAT)</h4>
<p><strong>Dose:</strong> 7920 cGy in 42 fractions (conventional fractionation)</p>
<p><strong>Technique:</strong> Volumetric Modulated Arc Therapy</p>
<p><strong>IGRT:</strong> Daily fiducial-based image guidance</p>
<p><strong>Acute Toxicity:</strong> Grade 2 GU (frequency/urgency), Grade 1 GI</p>
<p><strong>Outcome:</strong> Excellent PSA response (14.76 ‚Üí 0.8 ng/mL)</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">April 22, 2016</div>
<div class="timeline-content">
<h4>3-Month Post-RT Follow-up</h4>
<p><strong>PSA:</strong> 0.45 ng/mL (excellent response)</p>
<p><strong>Symptoms:</strong> Resolved GU toxicity, doing well</p>
<p><strong>Testosterone:</strong> 12 ng/dL (still suppressed, recovery expected)</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">October 22, 2016</div>
<div class="timeline-content">
<h4>9-Month Post-RT Follow-up (Current Visit)</h4>
<p><strong>PSA:</strong> 0.32 ng/mL (continued excellent response)</p>
<p><strong>Symptoms:</strong> None, excellent quality of life</p>
<p><strong>Testosterone:</strong> 125 ng/dL (recovery ongoing)</p>
<p><strong>Plan:</strong> Continue surveillance q3-4 months</p>
</div>
</div>
</div>
</div>
<!-- Recent Labs -->
<div class="section">
<h2>üî¨ Most Recent Laboratory Results (10/22/2016)</h2>
<table class="lab-table">
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Units</th>
<th>Reference Range</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA</td>
<td><strong>0.32</strong></td>
<td>ng/mL</td>
<td>0-4.0</td>
<td><span class="status-badge status-active">Excellent</span></td>
</tr>
<tr>
<td>Testosterone</td>
<td><strong>125</strong></td>
<td>ng/dL</td>
<td>300-1000</td>
<td><span class="status-badge status-completed">Recovering</span></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td><strong>14.3</strong></td>
<td>g/dL</td>
<td>13.5-17.5</td>
<td><span class="status-badge status-active">Normal</span></td>
</tr>
<tr>
<td>WBC</td>
<td><strong>7.2</strong></td>
<td>K/uL</td>
<td>4.5-11.0</td>
<td><span class="status-badge status-active">Normal</span></td>
</tr>
<tr>
<td>Creatinine</td>
<td><strong>0.9</strong></td>
<td>mg/dL</td>
<td>0.7-1.3</td>
<td><span class="status-badge status-active">Normal</span></td>
</tr>
<tr>
<td>ALT</td>
<td><strong>22</strong></td>
<td>U/L</td>
<td>7-56</td>
<td><span class="status-badge status-active">Normal</span></td>
</tr>
</tbody>
</table>
</div>
<!-- Current Medications -->
<div class="section">
<h2>üíä Current Medications</h2>
<table class="lab-table">
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Frequency</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin (Lipitor)</td>
<td>10 mg PO</td>
<td>Daily</td>
<td>Hyperlipidemia</td>
<td><span class="status-badge status-active">Active</span></td>
</tr>
<tr>
<td>Aspirin</td>
<td>81 mg PO</td>
<td>Daily</td>
<td>Cardiovascular prophylaxis</td>
<td><span class="status-badge status-active">Active</span></td>
</tr>
<tr>
<td>Vitamin D3</td>
<td>2000 IU PO</td>
<td>Daily</td>
<td>Bone health</td>
<td><span class="status-badge status-active">Active</span></td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>500 mg PO</td>
<td>BID</td>
<td>Bone health (post-ADT)</td>
<td><span class="status-badge status-active">Active</span></td>
</tr>
<tr>
<td>Multivitamin</td>
<td>1 tab PO</td>
<td>Daily</td>
<td>Nutritional support</td>
<td><span class="status-badge status-active">Active</span></td>
</tr>
</tbody>
</table>
</div>
<!-- Follow-up Plan -->
<div class="section">
<h2>üìã Follow-up Plan</h2>
<div class="timeline-content">
<h4>Prostate Cancer Surveillance</h4>
<ul style="margin-left: 20px; margin-top: 10px; line-height: 1.8;">
<li>PSA every 3-4 months for 2 years, then every 6 months for years 3-5</li>
<li>Monitor testosterone recovery (expect full recovery 12-18 months post-ADT)</li>
<li>Assess for late GU/GI toxicity at each visit</li>
<li>DEXA scan for bone density (ADT effect) - schedule for January 2017</li>
</ul>
<h4 style="margin-top: 20px;">Lynch Syndrome Surveillance (High Priority)</h4>
<ul style="margin-left: 20px; margin-top: 10px; line-height: 1.8;">
<li>Annual colonoscopy (status post APR, surveillance of remaining colon)</li>
<li>Annual urinalysis with cytology (bladder cancer risk)</li>
<li>Consider annual renal ultrasound or CT urography</li>
<li>Upper endoscopy every 3-5 years (gastric cancer risk)</li>
<li>Annual dermatologic examination (sebaceous tumors)</li>
<li>Maintain high clinical suspicion for new primary malignancies</li>
</ul>
<h4 style="margin-top: 20px;">Next Scheduled Appointments</h4>
<ul style="margin-left: 20px; margin-top: 10px; line-height: 1.8;">
<li><strong>Radiation Oncology:</strong> January 20, 2017 (Dr. Nicholas)</li>
<li><strong>Genetics:</strong> December 15, 2016 (Lynch surveillance planning)</li>
<li><strong>Primary Care:</strong> November 30, 2016 (routine annual physical)</li>
<li><strong>Gastroenterology:</strong> February 2017 (colonoscopy)</li>
</ul>
</div>
</div>
</div>
<div class="footer">
<p>Regional New Natalieborough Hospital | Department of Oncology</p>
<p>This document contains protected health information (PHI) and is confidential.</p>
<p>Generated: 10/22/2016 14:35 | Report ID: EHR-2016-10-789012</p>
</div>
</div>
</body>
</html>